Baseline characteristics of our patient population treated with Ven-based regimens
| Characteristics . | N = 120 . |
|---|---|
| Age, median (range) | 81 (80-94) |
| ECOG, median (range) | 1 (0-3) |
| ECOG ≥2, n (%) | 23 (19) |
| CIRS >6, n (%) | 65 (54) |
| TP53 disruption, n (%) | 32 (28) |
| Del(17p), n (%) | 25 (21) |
| TP53 mutation, n (%) | 21 (18) |
| Missing data, n (%) | 20 (17) |
| IGHV unmutated, n (%) | 67 (56) |
| High-risk genetic disease | 33 (28) |
| TLS risk categories | |
| Low risk, n (%) | 24 (20) |
| Intermediate risk, n (%) | 63 (53) |
| High risk, n (%) | 33 (28) |
| CrCl <60 mL/min, n (%) | 63 (53) |
| LDH ULN, n (%) | 61 (51) |
| Rai stages | |
| 0-I, n (%) | 35 (29) |
| II, n (%) | 27 (23) |
| III, n (%) | 27 (23) |
| IV, n (%) | 31 (26) |
| Binet stages | |
| A, n (%) | 15 (13) |
| B, n (%) | 47 (39) |
| C, n (%) | 58 (48) |
| Type of Ven regimen | |
| Ven monotherapy, n (%) | 60 (50) |
| Ven-R, n (%) | 45 (38) |
| Ven-G, n (%) | 17 (14) |
| Treatment naïve, n (%) | 20 (17) |
| Relapsed patients, n (%) | 100 (83) |
| Previous lines, median (range) | 2 (0-6) |
| 1, n (%) | 35 (29) |
| 2, n (%) | 34 (28) |
| ≥3, n (%) | 32 (27) |
| Type of previous therapy | |
| BTKi, n (%) | 51 (43) |
| Chlorambucil ± anti-CD20, n (%) | 43 (36) |
| FC-R, BR, n (%) | 48 (40) |
| Idelalisib-R, n (%) | 12 (10) |
| Others (alloSCT, lenalidomide, rituximab, CHOP, RCVP), n (%) | 17 (14) |
| BTKi pre-exposure, n (%) | 51 (43) |
| Efficacy (best response) | |
| ORR (CR + CRi + PR), n (%) | 109 (91) |
| SD, n (%) | 9 (8) |
| PD, n (%) | 2 (2) |
| Richter transformation, n (%) | 7 (6) |
| Characteristics . | N = 120 . |
|---|---|
| Age, median (range) | 81 (80-94) |
| ECOG, median (range) | 1 (0-3) |
| ECOG ≥2, n (%) | 23 (19) |
| CIRS >6, n (%) | 65 (54) |
| TP53 disruption, n (%) | 32 (28) |
| Del(17p), n (%) | 25 (21) |
| TP53 mutation, n (%) | 21 (18) |
| Missing data, n (%) | 20 (17) |
| IGHV unmutated, n (%) | 67 (56) |
| High-risk genetic disease | 33 (28) |
| TLS risk categories | |
| Low risk, n (%) | 24 (20) |
| Intermediate risk, n (%) | 63 (53) |
| High risk, n (%) | 33 (28) |
| CrCl <60 mL/min, n (%) | 63 (53) |
| LDH ULN, n (%) | 61 (51) |
| Rai stages | |
| 0-I, n (%) | 35 (29) |
| II, n (%) | 27 (23) |
| III, n (%) | 27 (23) |
| IV, n (%) | 31 (26) |
| Binet stages | |
| A, n (%) | 15 (13) |
| B, n (%) | 47 (39) |
| C, n (%) | 58 (48) |
| Type of Ven regimen | |
| Ven monotherapy, n (%) | 60 (50) |
| Ven-R, n (%) | 45 (38) |
| Ven-G, n (%) | 17 (14) |
| Treatment naïve, n (%) | 20 (17) |
| Relapsed patients, n (%) | 100 (83) |
| Previous lines, median (range) | 2 (0-6) |
| 1, n (%) | 35 (29) |
| 2, n (%) | 34 (28) |
| ≥3, n (%) | 32 (27) |
| Type of previous therapy | |
| BTKi, n (%) | 51 (43) |
| Chlorambucil ± anti-CD20, n (%) | 43 (36) |
| FC-R, BR, n (%) | 48 (40) |
| Idelalisib-R, n (%) | 12 (10) |
| Others (alloSCT, lenalidomide, rituximab, CHOP, RCVP), n (%) | 17 (14) |
| BTKi pre-exposure, n (%) | 51 (43) |
| Efficacy (best response) | |
| ORR (CR + CRi + PR), n (%) | 109 (91) |
| SD, n (%) | 9 (8) |
| PD, n (%) | 2 (2) |
| Richter transformation, n (%) | 7 (6) |
alloSCT, allogenic bone marrow stem cell transplantation; BR, bendamustine-rituximab; CHOP, cyclophosphamide, doxorubicine, vincristine, and prednisolone; CrCl, creatinine clearance; CR, complete response; CRi, complete response with incomplete count recovery; FC-R, fludarabine, cyclophosphamide and rituximab; idelalisib-R, idelalisib, rituximab; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial response; RCVP, rituximab, cyclophosphamide, vincristine and prednisolone; SD, stable disease; ULN, upper limit of normal.